On October 13, 2021 "Embrace innovation, and take root in Lin-gang" -- 2021 Shanghai International Biopharma Industry Week i.e. centralized signing ceremony for biopharmaceutical was held in Lin-gang Special Area.
As an emerging and premier CDMO technology service provider of biologics, Zencore Biologics is providing CMC services in cell line development, production process development, engineering scale-up, process characterization and verification, as well as commercial manufacturing. To fully support the research and development of innovative medicine and the commercialization of large molecular biologicals of domestic and foreign pharmaceutical enterprises, Zencore Biologics will build the global R&D headquarters and industrialization facility in Lin-gang. In addition to the existing phase I commercial manufacturing facility (2,000L disposable and 5,000L stainless steel), Zencore will build the phase II commercial manufacturing facility (15,000L single bioreactor) in the newly acquired land (55 mu, Chinese acre). Total investment of for phase I (~2 billion RMB) and phase II (1 billion RMB) commercial manufacturing facility will be nearly 3 billion RMB.
Zencore Biologics has witnessed the development and advancement of the Specical Area since its establishment in 2017 and intimately involved in the progress of the region. The fact that China will soon become the world's largest pharmaceutical market, combined with the strategic positioning of this special area in the national Innovation Initiative and Leading Example, make Pudong and Lin-gang the “Chinese parasol tree" for attracting and retaining top talents at home and abroad. With the accumulation of talents and resources, it is just a matter of time that Pudong and Lin-gang will become the largest and most innovative "industry leading areas" of biopharmaceuticals in the world. We will invest more capital, technical resources and human resources in Lin-gang to help build the biopharmaceutical industry cluster and serve domestic and foreign biomedical enterprises in the future, says Mr. Jianxin Chen, CEO of Zencore Biologics.
